Dr. Eric Topol asks, How can a drug that is associated with higher rates of both renal dysfunction and death than placebo — and that costs 50 times as much as standard therapies — be given to more than 600,000 patients and be promoted throughout the United States for serial outpatient use, an indication not listed on the label?
No takes yet. Share an insight, caveat, or question.
Eric J. Topol (2005) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: